Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Payables (2016 - 2019)

Historic Payables for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $1.7 million.

  • Soleno Therapeutics' Payables rose 3935.74% to $1.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $1.7 million, marking a year-over-year increase of 3935.74%. This contributed to the annual value of $934000.0 for FY2018, which is 4755.13% up from last year.
  • Per Soleno Therapeutics' latest filing, its Payables stood at $1.7 million for Q3 2019, which was up 3935.74% from $1.7 million recorded in Q2 2019.
  • In the past 5 years, Soleno Therapeutics' Payables ranged from a high of $1.7 million in Q2 2019 and a low of $410512.0 during Q4 2016
  • Moreover, its 5-year median value for Payables was $957000.0 (2016), whereas its average is $1.0 million.
  • Over the last 5 years, Soleno Therapeutics' Payables had its largest YoY gain of 10322.06% in 2016, and its largest YoY loss of 4093.83% in 2016.
  • Soleno Therapeutics' Payables (Quarter) stood at $695056.0 in 2015, then crashed by 40.94% to $410512.0 in 2016, then soared by 54.2% to $633000.0 in 2017, then skyrocketed by 47.55% to $934000.0 in 2018, then surged by 85.76% to $1.7 million in 2019.
  • Its Payables stands at $1.7 million for Q3 2019, versus $1.7 million for Q2 2019 and $1.3 million for Q1 2019.